3 Biotech Stocks to Avoid Right Now

Motley Fool2021-03-18

Here's why these attention-grabbing stocks could be toxic to your portfolio. Did you know that newbiotech stocksgo public at a rate of about one per week? With so many investment options in this ...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

Timtan85
2021-03-19
Timtan85
Comment pls tks
roadtoabilly
2021-03-18
roadtoabilly
do opposite of motley fool = profit
- Timtan85:
  Haha yeah
干三小
2021-03-18
干三小
BULLSHIT
AlvinTang
2021-03-18
AlvinTang
Okay
- Kingoftrade:
  Ok
HOCK
2021-03-18
HOCK
Avoid = buy
- 33a3e628:
  like pla
Rache13
2021-03-18
Rache13
Yes

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/1142227040?lang=zh_CN&edition=full","thumbnail":"","is_english":true,"pubTime":"2021-03-18 20:24","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1142227040","market":"us","top_or_hot":-1,"title":"3 Biotech Stocks to Avoid Right Now","media":"Motley Fool","content":"<div>\n<p>Here's why these attention-grabbing stocks could be toxic to your portfolio.\n\nDid you know that newbiotech stocksgo public at a rate of about one per week? With so many investment options in this ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/03/18/3-biotech-stocks-to-avoid-right-now/\">网页链接</a>\n\n</div>\n","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>3 Biotech Stocks to Avoid Right Now</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n3 Biotech Stocks to Avoid Right Now\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-03-18 20:24 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/03/18/3-biotech-stocks-to-avoid-right-now/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Here's why these attention-grabbing stocks could be toxic to your portfolio.\n\nDid you know that newbiotech stocksgo public at a rate of about one per week? With so many investment options in this ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/03/18/3-biotech-stocks-to-avoid-right-now/\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"SAVA","symbol_name":"Cassava Sciences Inc","start_time":0,"source_url":"https://www.fool.com/investing/2021/03/18/3-biotech-stocks-to-avoid-right-now/","article_id":"1142227040","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1142227040","pubTimestamp":1616070253,"columns":[],"sourceInfo":null,"weMediaInfo":null,"summary":"Here's why these attention-grabbing stocks could be toxic to your portfolio.\n\nDid you know that newb","collect":0,"end_time":0,"defaultTopTitle":"fool.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"SAVA":"Cassava Sciences Inc","RUBY":"Rubius Therapeutics, Inc.","OCGN":"Ocugen"},"translate_title":"3个生物科技股当前应回避","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"OCGN":0.9,"RUBY":0.9,"SAVA":0.9},"content_text":"Here's why these attention-grabbing stocks could be toxic to your portfolio.\n\nDid you know that newbiotech stocksgo public at a rate of about one per week? With so many investment options in this space to choose from, it's a little surprising that some of the most popular companies right now haven't had much success when it comes to drug development.\nEvery business has a story to tell, and plenty of investors like what they've been hearing from these three. Before following the crowd, though, you should know that there are potholes along these companies' paths to success.\n1. Cassava Sciences\nThis company's developing a potential new Alzheimer's disease drug called simufilam. In the U.S., 1 in 9 people over the age of 65 have Alzheimer's disease, but there still aren't any available treatments for this progressive and ultimately fatal disease. As the first, simufilam could become one of the top-selling drugs of its time.\nFollowing a successful phase 2 trial, Cassava Sciences told investors the Food and Drug Administration (FDA) gave the green light for a pair of phase 3 trials slated to begin in the second half of the year. If simufilam succeeds at both, shares of this biotech could explode higher.\nUnfortunately, Cassava Sciences has been developing simufilam for over a decade and it still doesn't have any evidence from a randomized controlled trial that simufilam works as intended.\nThe company included a placebo group in a smallphase 2study that read out last year, but simufilam failed to reduce signs of inflammation that show up in fluid that bathes the brain. Investigators also gave Alzheimer's disease patients cognitive tests to see if simufilam actually made a difference, but they couldn't measure an improvement.\n2. Ocugen\nShares of this clinical-stage drugmaker have been soaring in response to good news for a COVID-19 vaccine called Covaxin. The vaccine's developer, Bharat Biotech, is a well-established vaccine manufacturer headquartered in India.\nBharat Biotech has hired Ocugen to co-develop Covaxin for the U.S. market, and it looks like a winner. In a phase 3 study with over 25,000 volunteers, Covaxin was about 81% effective at preventing COVID-19 infections in India.\nBefore buying any Ocugen shares, you should know that the FDA wasn't willing to consider emergency use authorization requests without data from lots of U.S. trial volunteers when there were zero COVID-19vaccines available. Now that the agency has already authorized three safe and effective options, there's zero chance that Ocugen will sell Covaxin in the U.S. without a new phase 3 trial.\n3. Rubius Therapeutics\nThis clinical-stage biotech is developing new cancer therapies made from a line of red blood cells that can be taken off a shelf and administered as soon as they're prescribed. Shares of Rubius have soared this year, thanks to some tumor shrinkage observed in an early-stage study with a variety of cancer patients taking its lead candidate RTX-240.\nIn an interim assessment of an ascending-dosage trial that had data from 16 volunteers available, two of the patients have responded well to RTX-240 treatment. While this looks like a pretty good result for an interim analysis of an early trial, it's probably too early for anyone at Rubius to begin celebrating. That's because the only confirmed tumor shrinkage presented so far occurred for a patient treated with the lowest dosage tested.\nRubius Therapeutics' red blood cells are engineered to excite and enlist different types of white blood cells to take action against tumors. The company was able to show expansion of natural killer cells and T-cells for eight patients earlier this year. Unfortunately, the company hasn't been able to show RTX-240 expanded these tumor-fighting cells for the patients who responded.\nLooking forward\nAll of these companies have huge market valuations right now that could come crashing down if their lead programs can't deliver. That's because there's nearly nothing for them to fall back on.\nOcugen doesn't have any potential new drugs in clinical trials right now, and it's going to be a long time before we know if the gene therapies it intends to develop have a shot at success. Cassava Sciences has a potential new test for biomarkers that could indicate Alzheimer's disease, but simufilam is the only clinical-stage new drug candidate in its pipeline.\nRubius Therapeutics is developing a platform of red-blood-cell-based treatments, and the company already has a second candidate cleared by the FDA to begin clinical trials. If any of these companies has a fallback if its lead candidate doesn't work out, it's Rubius. That said, it's still way too risky to consider putting in your portfolio at the moment.","kind":"news","is_publish_news":true,"is_publish_highlight":true,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[{"id":350136730,"gmtCreate":1616165144620,"gmtModify":1634526906656,"author":{"id":"3573460795152662","authorId":"3573460795152662","name":"Timtan85","avatar":"https://static.tigerbbs.com/5ac241a703d94ceba483abb0655d0b6b","vip":1,"crmLevel":2,"crmLevelSwitch":0,"idStr":"3573460795152662","authorIdStr":"3573460795152662"},"htmlText":"Comment pls tks","listText":"Comment pls tks","text":"Comment pls tks","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/350136730","repostId":1142227040,"repostType":2,"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":327880874,"gmtCreate":1616076200298,"gmtModify":1634527360283,"author":{"id":"3573195863338760","authorId":"3573195863338760","name":"roadtoabilly","avatar":"https://static.tigerbbs.com/beb7f54a4010b0964d99563c43e76423","vip":1,"crmLevel":2,"crmLevelSwitch":0,"idStr":"3573195863338760","authorIdStr":"3573195863338760"},"htmlText":"do opposite of motley fool = profit","listText":"do opposite of motley fool = profit","text":"do opposite of motley fool = profit","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/327880874","repostId":1142227040,"repostType":2,"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":3837014,"gmtCreate":1616165153130,"gmtModify":1635752068613,"authorId":3573460795152662,"author":{"id":3573460795152662,"idStr":"3573460795152662","authorId":3573460795152662,"name":"Timtan85","avatar":"https://static.tigerbbs.com/5ac241a703d94ceba483abb0655d0b6b","vip":1,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":327880874,"type":1,"supId":0,"prevId":0,"content":"Haha yeah","text":"Haha yeah","html":"Haha yeah"}],"langContent":"EN"},{"id":327804928,"gmtCreate":1616074891464,"gmtModify":1634527373059,"author":{"id":"3571736454766702","authorId":"3571736454766702","name":"干三小","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"crmLevel":2,"crmLevelSwitch":0,"idStr":"3571736454766702","authorIdStr":"3571736454766702"},"htmlText":"BULLSHIT","listText":"BULLSHIT","text":"BULLSHIT","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/327804928","repostId":1142227040,"repostType":2,"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":327178949,"gmtCreate":1616074372681,"gmtModify":1634527378763,"author":{"id":"3561683872711062","authorId":"3561683872711062","name":"AlvinTang","avatar":"https://static.tigerbbs.com/76e114f543425a2d046a65fe4951f729","vip":1,"crmLevel":5,"crmLevelSwitch":0,"idStr":"3561683872711062","authorIdStr":"3561683872711062"},"htmlText":"Okay","listText":"Okay","text":"Okay","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/327178949","repostId":1142227040,"repostType":4,"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":3827153,"gmtCreate":1616074894312,"gmtModify":1635752592164,"authorId":3578300377977006,"author":{"id":3578300377977006,"idStr":"3578300377977006","authorId":3578300377977006,"name":"Kingoftrade","avatar":"https://static.tigerbbs.com/3716438e8901825672ffa000f27e79cc","vip":1,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":327178949,"type":1,"supId":0,"prevId":0,"content":"Ok","text":"Ok","html":"Ok"}],"langContent":"EN"},{"id":327163699,"gmtCreate":1616070769411,"gmtModify":1634527398702,"author":{"id":"3574326262963990","authorId":"3574326262963990","name":"HOCK","avatar":"https://static.tigerbbs.com/88799e7ae4e69750fd2f85687a24a9e3","vip":1,"crmLevel":3,"crmLevelSwitch":0,"idStr":"3574326262963990","authorIdStr":"3574326262963990"},"htmlText":"Avoid = buy","listText":"Avoid = buy","text":"Avoid = buy","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/327163699","repostId":1142227040,"repostType":4,"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":3826738,"gmtCreate":1616072620288,"gmtModify":1635752605596,"authorId":3574574983539751,"author":{"id":3574574983539751,"idStr":"3574574983539751","authorId":3574574983539751,"name":"33a3e628","avatar":"https://community-static.tradeup.com/news/default-avatar.jpg","vip":1,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":327163699,"type":1,"supId":0,"prevId":0,"content":"like pla","text":"like pla","html":"like pla"}],"langContent":"EN"},{"id":327187261,"gmtCreate":1616070537153,"gmtModify":1634527400776,"author":{"id":"3573532802717234","authorId":"3573532802717234","name":"Rache13","avatar":"https://static.tigerbbs.com/ccf273862879d166aad5128bba7a8589","vip":1,"crmLevel":2,"crmLevelSwitch":0,"idStr":"3573532802717234","authorIdStr":"3573532802717234"},"htmlText":"Yes","listText":"Yes","text":"Yes","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/327187261","repostId":1142227040,"repostType":4,"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"}],"isCommentEnd":false,"newsSizeData":{"likeSize":17,"commentSize":8,"repostSize":0,"favoriteSize":3,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.29.3","shortVersion":"4.29.3","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1142227040"}